Emerging studies suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , appears to represent a promising advancement for obesity management . Initial human investigations have indicated https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026